Drug spend is the second-largest expense line in most hospital operating budgets, trailing only labor. And unlike labor costs, pharmaceutical spend has a set of proven, systematic levers that pharmacy directors can pull to generate meaningful savings — often without any reduction in formulary breadth or patient care quality.

Over 38 years of working with hospital pharmacies across the country, my team at IMC Pharma has helped health systems reduce their pharmaceutical costs by an average of 30%. That is not a rounding error. On a $5 million annual drug budget, 30% is $1.5 million that goes back to the health system every year.

Here is how we do it.

The most common mistake I see pharmacy directors make is trying to optimize purchasing before they have an accurate picture of what they already own.

You cannot make good buying decisions if you do not know what is sitting on your shelves. Phantom inventory — drugs that appear in your system but are not physically present — leads to unnecessary purchasing. Untracked inventory — drugs on the shelves that are not in your system — leads to waste and compliance exposure.

Before any cost reduction initiative, you need a clean, accurate physical inventory. This is not optional. Every dollar you spend on a professional inventory count pays back many times over in purchasing efficiency alone.

If your hospital is a member of a Group Purchasing Organization like Premier Inc., you have access to negotiated pricing that can represent 15% to 25% savings versus open-market rates. But those savings only materialize if your purchasing is actually flowing through the contracted channels.

In my experience, the average hospital pharmacy is only capturing 70% to 80% of available GPO savings. The gap comes from:

• Purchasing off-contract when contracted items are temporarily out of stock, then failing to switch back
• Using non-preferred vendors for categories where preferred pricing exists
• Missing contract tier thresholds because purchasing is fragmented across multiple cost centers
• Formulary items that have never been mapped to their GPO contract equivalents

A systematic GPO compliance review — comparing every line item on your purchasing history against your contracted formulary — typically surfaces 10% to 15% in immediate savings opportunities.

Every hospital pharmacy accumulates expired, near-expiry, and recalled medications. Most pharmacies treat this as a disposal cost. The ones that manage it well treat it as a revenue recovery opportunity.

Through a properly managed reverse distribution program, hospitals can recover manufacturer credits on a significant portion of their expired drug inventory. The exact recovery rate depends on the drugs involved — brand-name medications typically carry higher credit values than generics — but the average hospital I work with recovers between $40,000 and $120,000 annually through reverse distribution.

The key is timing. Drugs that are within 6 months of expiration but not yet expired are eligible for return credit at most manufacturers. Once they expire, that window closes. A proactive expiration monitoring program — pulling items at the 90-day mark and submitting them for return — maximizes your credit recovery.

IMC Pharma's reverse distribution service handles the entire process: physical removal, documentation, manufacturer submission, and credit tracking. Most of our clients see a positive ROI within the first engagement.

Par levels set in a pharmacy information system have a way of becoming permanent fixtures, even when the clinical reality has changed. A unit that was running 40 patients two years ago may now run 28 — but the par levels for that unit's ADCs have never been adjusted.

Overstocked ADCs are a direct cost. Drugs sitting in pockets that are not being used are capital tied up in inventory that could be deployed elsewhere. They are also an expiration risk — items that sit too long in ADCs are the ones that expire unnoticed.

A systematic par level review — comparing actual dispensing velocity against current par settings for every ADC pocket — typically identifies 15% to 20% of ADC inventory as overstocked. Rightsizing those pockets frees up working capital and reduces waste.

Every hospital formulary accumulates therapeutic duplicates over time. Two drugs in the same class, with similar efficacy profiles, but significantly different costs. The clinical team may have a slight preference for one, but the preference is rarely strong enough to justify a 3x price differential.

A structured formulary rationalization process — working with your P&T committee to identify and eliminate therapeutic duplicates — can generate substantial savings without meaningful clinical impact. The key is presenting the data clearly: here are the two drugs, here is the efficacy evidence, here is the cost difference, here is the annual savings from standardizing to the lower-cost option.

I am not suggesting that cost should override clinical judgment. I am suggesting that when clinical judgment is genuinely equivalent, cost should be the tiebreaker — and that conversation needs to happen with data, not anecdote.

For qualifying hospitals, the 340B drug pricing program is one of the most powerful cost reduction tools available. Eligible hospitals can purchase covered outpatient drugs at significantly discounted prices — discounts that average 25% to 50% below wholesale acquisition cost.

But 340B savings only materialize if the program is managed correctly. Split billing compliance, eligibility documentation, and audit readiness are not optional — they are the price of admission. HRSA audits are increasing in frequency, and the consequences of non-compliance include repayment obligations and program termination.

The pharmacies that maximize 340B savings are the ones that treat it as a managed program, not a passive discount. That means dedicated 340B coordinator resources, regular internal audits, and a documented compliance framework.

IV compounded preparations represent one of the highest per-unit costs in the pharmacy — and one of the highest waste rates. Bags prepared but not administered, preparations that exceed their beyond-use date before use, and batch sizes that do not match actual utilization patterns all contribute to compounding waste that can represent 5% to 10% of total compounding costs.

Reducing compounding waste requires accurate utilization data. How many bags of each preparation are actually being administered versus prepared? What is the average time from preparation to administration? Are batch sizes aligned with actual demand patterns?

With that data in hand, you can right-size your compounding batches, adjust your preparation schedules, and implement a just-in-time compounding model for lower-volume preparations — all of which reduce waste without compromising availability.

None of these strategies is a silver bullet on its own. But implemented together, as part of a systematic pharmacy cost management program, they compound into results that can transform a pharmacy's financial performance.

The 30% average cost reduction my team achieves is not from one big intervention. It is from doing 10 things right simultaneously — accurate inventory, GPO compliance, reverse distribution, par level optimization, formulary rationalization, 340B management, and waste reduction — and then maintaining the discipline to keep doing them right every year.

If you are a pharmacy director who knows your drug costs are higher than they should be but are not sure where to start, I would be glad to have a conversation. A no-obligation assessment of your current pharmacy operations is often the clearest way to identify where the biggest opportunities are.

Michael Samojla is the CEO of IMC Pharma and a nationally recognized expert in hospital pharmacy inventory management with 38 years of experience serving more than 1,000 healthcare facilities.